Remove 2023 Remove Biosimilars Remove Process Improvement
article thumbnail

Single-use technology propelling upstream bioprocessing market expansion

European Pharmaceutical Review

Based on the report’s data, the market is also advancing due to greater amount of research being conducted on the production of biosimilars/biomolecules, monoclonal antibodies, and tiny therapeutic peptides.

article thumbnail

NHC Submits Comments on CMS Draft Guidance for IPAY 2028

Putting Patients First Blog

CMS should draw on lessons from previous transitions, including biosimilar coverage rollouts and site-of-care policy shifts, to avoid known implementation pitfalls. April 14, 2023. Even well-intentioned policies can create access disparities if communication and operational support are lacking. July 2, 2024. link] 2027_07.02.24.pdf.

article thumbnail

The next frontier: Global leadership in biopharma

Express Pharma

With advancements in biotechnology, robust scientific capabilities, cost-effective manufacturing processes, a large workforce and a shift towards more complex biologic drugs, India is at the cusp of a huge opportunity to emerge as a leader in biopharma. Only then can tomorrow’s giant businesses emerge from today’s unicorns.”